Akebia Therapeutics’ (AKBA) Buy Rating Reiterated at Mizuho
Other research analysts also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research report on Wednesday, November 15th. Zacks Investment Research raised shares of Akebia Therapeutics from a hold rating to a buy rating and set a $17.00 price objective on the stock in a research report on Monday, November 13th. BTIG Research initiated coverage on shares of Akebia Therapeutics in a research report on Thursday, December 7th. They set a buy rating and a $30.00 price objective on the stock. ValuEngine upgraded shares of Akebia Therapeutics from a sell rating to a hold rating in a research note on Thursday, March 1st. Finally, Piper Jaffray Companies initiated coverage on shares of Akebia Therapeutics in a research note on Monday, December 18th. They issued an overweight rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Akebia Therapeutics presently has an average rating of Buy and a consensus price target of $22.20.
Akebia Therapeutics (NASDAQ AKBA) opened at $12.59 on Tuesday. Akebia Therapeutics has a 52-week low of $8.69 and a 52-week high of $20.25.
Several hedge funds have recently added to or reduced their stakes in AKBA. Macquarie Group Ltd. acquired a new stake in shares of Akebia Therapeutics in the 3rd quarter worth $183,000. Teacher Retirement System of Texas acquired a new stake in shares of Akebia Therapeutics in the fourth quarter valued at about $188,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Akebia Therapeutics in the third quarter valued at about $200,000. Caxton Associates LP acquired a new stake in shares of Akebia Therapeutics in the third quarter valued at about $246,000. Finally, Voya Investment Management LLC lifted its stake in shares of Akebia Therapeutics by 11.7% in the second quarter. Voya Investment Management LLC now owns 18,454 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 1,933 shares during the period. Institutional investors own 71.23% of the company’s stock.
WARNING: “Akebia Therapeutics’ (AKBA) Buy Rating Reiterated at Mizuho” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/03/14/akebia-therapeutics-akba-buy-rating-reiterated-at-mizuho.html.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.